GlassScriptPhysician profile
Brittany Utley
NPI 1508681503
$3,401.46
in general payments reported to CMS, 2019-2025
22 companies · $3,401 in 2025
The $3,401 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $454.48 | 2025 | Auvelity |
| Abbvie INC. | $451.27 | 2025 | |
| Vanda Pharmaceuticals INC. | $418.91 | 2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $415.81 | 2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $287.17 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $265.63 | 2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $206.32 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.23 | 2025 | Caplyta |
| Bausch Health US, LLC | $135.86 | 2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $133.64 | 2025 | Cobenfy |
| Indivior INC. | $107.75 | 2025 | Sublocade |
| Alkermes, INC. | $64.92 | 2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $56.34 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $54.85 | 2025 | Trintellix |
| Tris Pharma INC | $33.73 | 2025 | Dyanavel Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $32.32 | 2025 | |
| Lilly USA, LLC | $28.60 | 2025 | Zepbound |
| Supernus Pharmaceuticals, INC. | $27.97 | 2025 | Qelbree |
| Tms Neurohealth Centers INC. | $18.49 | 2025 | Tms Neurohealth Centers INC. |
| Luye Pharma (USA) LTD. | $18.23 | 2025 | Erzofri Extended-Release |
| Braeburn INC. | $18.04 | 2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $13.90 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Utley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.